OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/19/2026
Back to search
Official data from USPTO
ALPIONER THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
ALPIONER THERAPEUTICS
ST13
US500000079405529Class
1, 5, 42
Filing
79405529
Registration
7781364
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
04/03/2026
Classification
Registered
Trademark type
Word
Nice classes
1, 5, 42
Filing date
07/02/2024
Registration date
05/06/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/06/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
34
Owner location
FR
Examiner
CORWIN, KEVIN SCOTT
Law office
M30
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
A. T. (pessoa física)
Representatives
JANET G RICCIUTI JANET GILBERT RICCIUTI PC
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in the manufacture of human pharmaceutical and vaccine products and veterinary pharmaceutical and vaccine products; Plant extractsactive ingredients and excipientsother than essential oilsused in the manufacture of human pharmaceutical and vaccine products and veterinary pharmaceutical and vaccine products; Antibodies used in the manufacture of active vaccine ingredients
Class 5
Pharmaceutical productspharmaceutical preparations for the diagnosisthe preventionthe monitoring and the treatment of cancerscommunity and hospital-acquired infectionschronic respiratory diseaseswounds healing; Pharmaceutical productsantibodies and monoclonal antibodies for medical purposes; Veterinary productsveterinary pharmaceutical preparations for the diagnosisthe preventionthe monitoring and the treatment of cancerscommunity and hospital-acquired infectionschronic respiratory diseaseswounds healing; Vaccines for human use; Vaccines for veterinary use
Class 42
Medical research services; scientific research for medical purposes; Research and development of vaccines and medicines
Publications
History of USPTO decisions and trademark events.
26 publications found
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/02/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/02/2026
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/25/2025
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/05/2025
FIMP
FINAL DISPOSITION PROCESSED
12/05/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/02/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/07/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/06/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
05/06/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/18/2025
PUBO
PUBLISHED FOR OPPOSITION
03/18/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/12/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/25/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/25/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/25/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/25/2025
RFNT
REFUSAL PROCESSED BY IB
02/15/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/30/2025
RFRR
REFUSAL PROCESSED BY MPU
01/30/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/28/2024
CNRT
NON-FINAL ACTION WRITTEN
12/27/2024
DOCK
ASSIGNED TO EXAMINER
12/27/2024
MAFR
APPLICATION FILING RECEIPT MAILED
10/09/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/09/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/03/2024
Continuous trademark protection
Get notified about every new filing that threatens ALPIONER THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.